Revvity, Inc. (RVTY)

NYSE: RVTY · Real-Time Price · USD
92.89
-1.10 (-1.17%)
May 5, 2025, 4:00 PM EDT - Market closed
-1.17%
Market Cap 11.16B
Revenue (ttm) 2.77B
Net Income (ttm) 286.61M
Shares Out 120.15M
EPS (ttm) 2.35
PE Ratio 39.52
Forward PE 18.30
Dividend $0.28 (0.30%)
Ex-Dividend Date Jul 18, 2025
Volume 705,296
Open 93.25
Previous Close 93.99
Day's Range 92.77 - 94.09
52-Week Range 89.36 - 129.50
Beta 1.02
Analysts Buy
Price Target 126.08 (+35.73%)
Earnings Date Apr 28, 2025

About RVTY

Revvity, Inc. provides health sciences solutions, technologies, and services worldwide. The company’s Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and DNA sequencing services. Its Diagnostics segment offers instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for tes... [Read more]

Sector Healthcare
Founded 1937
Employees 11,000
Stock Exchange NYSE
Ticker Symbol RVTY
Full Company Profile

Financial Performance

In 2024, Revvity's revenue was $2.76 billion, an increase of 0.16% compared to the previous year's $2.75 billion. Earnings were $270.39 million, a decrease of -60.99%.

Financial Statements

Analyst Forecast

According to 13 analysts, the average rating for RVTY stock is "Buy." The 12-month stock price forecast is $126.08, which is an increase of 35.73% from the latest price.

Price Target
$126.08
(35.73% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Revvity to Present at Upcoming Investor Conferences

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced it will present at the following investor conferences: Bank of America Global Healthcare Conference 2025 Tuesday, May 13, 2...

5 days ago - Business Wire

Revvity, Inc. (RVTY) Q1 2025 Earnings Call Transcript

Revvity, Inc. (NYSE:RVTY) Q1 2025 Earnings Conference Call April 28, 2025 8:00 AM ET Company Participants Steve Willoughby - Senior Vice President, Investor Relations Prahlad Singh - President & Chie...

7 days ago - Seeking Alpha

Life Science Tools Maker Revvity Delivers Strong Q1 Earnings Despite Evolving Macroeconomic Backdrop

Revvity Inc. RVTY stock is trading higher on Monday after the company reported better-than-expected first-quarter 2025 earnings.

7 days ago - Benzinga

Revvity beats quarterly estimates on steady demand for medical equipment

Revvity reported first-quarter results above Wall Street estimates and maintained its full-year profit forecast on Monday, helped by steady demand from biotech clients for medical equipment used for d...

7 days ago - Reuters

Revvity Announces Financial Results for the First Quarter of 2025

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today reported financial results for the first quarter ended March 30, 2025. The Company reported GAAP earnings per share of $0.35, as comp...

7 days ago - Business Wire

Revvity Board Declares Quarterly Dividend

WALTHAM, Mass.--(BUSINESS WIRE)--The Board of Directors of Revvity (NYSE: RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on August 8, 2...

11 days ago - Business Wire

Watchmaker Genomics and Revvity Team to Automate and Streamline NGS Library Preparation

BOULDER, Colo.--(BUSINESS WIRE)-- #NGS--Watchmaker Genomics, a leader in high-performance genomics solutions, today announced an important milestone in providing comprehensive and robust automated sol...

12 days ago - Business Wire

Revvity Fuels the Future of Cancer Science with New Research Solutions

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc., is set to unveil the VivoJect™ Image-Guided Injection System as part of its distinguished cancer research and discovery portfolio at the AACR Annual Mee...

Other symbols: RSSS
13 days ago - Business Wire

Revvity to Hold Earnings Call on Monday, April 28, 2025

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced that it will release its first quarter 2025 financial results prior to market open on Monday, April 28, 2025. The Company w...

4 weeks ago - Business Wire

Revvity Signals Software Unveils Unified Data Platform to Accelerate Drug Discovery

WALTHAM, Mass.--(BUSINESS WIRE)--Today, Revvity, Inc. announced that its software and informatics division, Revvity Signals Software, will launch its Signals One™, a unified software platform evolved ...

4 weeks ago - Business Wire

Revvity Secures FDA Approval for Improved Automated Latent Tuberculosis Test

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced that the U.S. Food and Drug Administration (FDA) has approved the Auto-Pure 2400 liquid handling platform with the T-SPOT™....

4 weeks ago - Business Wire

Revvity Expands Alliance with Genomics England to Drive Research into Newborn Genomic Sequencing in England

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity announced an agreement with Genomics England to further collaborate on the Generation Study by providing sequencing services.

6 weeks ago - Business Wire

PerkinElmer Acquires Project Farma, Expanding Its OneSource Professional Services Offering for the Life Sciences Industry

SHELTON, Conn.--(BUSINESS WIRE)--PerkinElmer, a global leader in analytical solutions and specialized services for (bio)pharma, applied and food markets, today announced the acquisition of Project Far...

7 weeks ago - Business Wire

Revvity's EUROIMMUN Receives CE Mark for Novel Measles Antibody Detection Assay

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced the launch of EUROIMMUN's CE-marked Anti-Measles Virus ELISA 2.0 (IgG) to support the diagnosis of a measles virus infectio...

2 months ago - Business Wire

Revvity Wins Permanent Injunction Enforcing Agreements with Cloud Software Group

WALTHAM, Mass.--(BUSINESS WIRE)--Today, Revvity, Inc. (NYSE: RVTY) announced that the Massachusetts Superior Court has ruled in its favor and will issue a permanent injunction to enforce Revvity's rig...

2 months ago - Business Wire

Revvity, Inc. (RVTY) Q4 2024 Earnings Call Transcript

Revvity, Inc. (NYSE:RVTY) Q4 2024 Earnings Conference Call January 31, 2025 8:00 AM ET Company Participants Steve Willoughby - Senior Vice President, Investor Relations Prahlad Singh - President & Ch...

3 months ago - Seeking Alpha

Revvity forecasts 2025 revenue, profit below estimates amid weak biotech spending

Medical equipment maker Revvity forecast full-year profit and revenue for 2025 below Wall Street estimates on Friday, as it expects soft demand for its products and services used in drug research.

3 months ago - Reuters

Revvity Announces Financial Results for the Fourth Quarter and Full Year of 2024

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) today reported financial results for the fourth quarter and full year ended December 29, 2024. Fourth Quarter 2024 The Company reported GAAP...

3 months ago - Business Wire

Revvity Ignites Scientific Breakthroughs at SLAS2025

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. is set to unveil its groundbreaking new Phenologic.AI™ software at SLAS2025 in San Diego, January 27-29. Designed to redefine cellular imaging workflows ...

3 months ago - Business Wire

Revvity and Element Biosciences Collaborate to Advance Sequencing-based IVD Neonatal Testing

WALTHAM, Mass. & SAN DIEGO--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced a strategic agreement to commercialize an in vitro diagnostic (IVD) workflow solution for neonatal sequencing, ...

4 months ago - Business Wire

Revvity to Hold Earnings Call on Friday, January 31, 2025; Provides Update on Financial Performance

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced that it will release its fourth quarter and full year 2024 financial results prior to market open on Friday, January 31, 20...

4 months ago - Business Wire

Revvity Announces FDA Clearance for First Automated Free Testosterone Test

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced that it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for EUROIMMUN's automated chemiluminesce...

4 months ago - Business Wire

Revvity to Present at J.P. Morgan Healthcare Conference

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) will present at the 43rd annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 8:15 a.m. PT in San Francisco, CA. Presiden...

4 months ago - Business Wire

Safe Biopharma: Revvity's Recurring Revenues And Diagnostics

Revvity, Inc. is a leader in life sciences and diagnostics with diversified revenue streams and a strong balance sheet, making it a low-risk biopharma play. The company's recurring revenue base (80%) ...

5 months ago - Seeking Alpha

Despite Higher Valuations, Some Life Sciences Tools Stocks Create Good Opportunities: Analyst

BofA Securities reports that the Life Sciences Tools sector struggled in fiscal year 2024.

Other symbols: DHR
5 months ago - Benzinga